Trial Profile
An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Velaglucerase alfa (Primary) ; Vitamin D
- Indications Gaucher's disease type I
- Focus Therapeutic Use
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 04 Dec 2020 Status changed from active, no longer recruiting to completed.
- 14 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Dec 2018 This trial has been completed in Germany.